Clinical Trial Update: Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study comparing the tocilizumab biosimilar Complarate with Actemra in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)
• Complarate (tocilizumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED